Claims for Patent: 9,259,425

Summary for Patent: 9,259,425

Title:	Compositions and methods for eye whitening
Abstract:	The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective .alpha.-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
Inventor(s):	Horn; Gerald (Deerfield, IL)
Assignee:	Eye Therapies LLC (Dana Point, CA)
Application Number:	14/044,929
Patent Claims:	1. A method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising from between about 0.001% to about 0.05% weight by volume of a selective .alpha.-2 adrenergic receptor agonist selected from lofexidine, apraclonidine, mivazerol, clonidine, brimonidine, alpha methyl dopa, guanfacine, dexmedetomidine, (+)-(S)-4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, and 1-[(imidazolidin-2-yl)imino]indazole, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein said .alpha.-2 adrenergic receptor agonist is brimonidine at a concentration from between about 0.01% to about 0.025% weight by volume. 3. A method of reducing redness of an eye comprising administering to a subject in need thereof a composition comprising from between about 0.001% to about 0.05% weight by volume of a selective .alpha.-2 adrenergic receptor agonist selected from lofexidine, apraclonidine, mivazerol, clonidine, brimonidine, alpha methyl dopa, guanfacine, dexmedetomidine, (+)-(S)-4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, and 1-[(imidazolidin-2-yl)imino]indazole, or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein said .alpha.-2 adrenergic receptor agonist is brimonidine at a concentration from between about 0.01% to about 0.025% weight by volume. 5. A method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising from between about 0.001% to about 0.05% weight by volume of a selective .alpha.-2 adrenergic receptor agonist selected from lofexidine, apraclonidine, mivazerol, clonidine, brimonidine, alpha methyl dopa, guanfacine, dexmedetomidine, (+)-(S)-4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, and 1-[(imidazolidin-2-yl)imino]indazole, or a pharmaceutically acceptable salt thereof. 6. The method of claim 5, wherein said .alpha.-2 adrenergic receptor agonist is brimonidine at a concentration from between about 0.01% to about 0.025% weight by volume.